Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page has been updated to include a government-status notice and a version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%
- Check18 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release. No other content changes were detected.SummaryDifference0.1%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; no core content or business data changes observed. The Back to Top link was removed, a minor UI change.SummaryDifference0.2%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check47 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while key content related to pembrolizumab and various medical topics has been removed.SummaryDifference3%
- Check61 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.